<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18169">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02870361</url>
  </required_header>
  <id_info>
    <org_study_id>086/2016BO1</org_study_id>
    <nct_id>NCT02870361</nct_id>
  </id_info>
  <brief_title>Influence of Central Nervous Insulin Sensitivity on Insulin Secretion</brief_title>
  <official_title>Einfluss Der zentralnervösen Insulinsensitivität Auf Die Insulinsekretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance is a central pathophysiological component of type 2 diabetes and is
      associated with a high risk of cardiovascular disease. The tissue in which it manifests are
      mainly muscle, liver, and adipose tissue. Since the transport of glucose to the brain is
      independent of insulin, this organ has traditionally not been studied in this regard. In
      animal experiments, however, knockout of the insulin receptor in the brain leads to obesity
      and peripheral insulin resistance. This finding of insulin action in the brain could also be
      confirmed in human studies.

      The investiagtors intend to investigate whether central nervous insulin action affects
      insulin secretion in humans. For this purpose, nasal insulin and placebo are administered 15
      minutes before a hyperglycemic hyperinsulinemic clamps, which stimulate insulin secretion.
      Insulin sensitivity of the brain is measured by a an established protocol with functional
      magnetic resonance imaging before and after nasal insulin administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin secretion assessed as serum C-peptide levels during a hyperglycemic clamp</measure>
    <time_frame>0-10 min during hyperglycemic clamp and 10-90 min during hyperglycemic clamp</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation with brain insulin sensitivity</measure>
    <time_frame>15-30 minutes post insulin nasal spray</time_frame>
    <description>Correlation of regional brain insulin sensitivity with the change of pancreatic insulin secretion due to central action of insulin. Changes in regional cerebral blood flow from before to after intransal insulin administration will be assessed by fMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differential effects in lean and overweight</measure>
    <time_frame>0-10 min during hyperglycemic clamp and 10-90 min during hyperglycemic clamp</time_frame>
    <description>Differences in the effect of nasal insulin versus placebo on C-peptide levels during a hyperglycemic clamp between lean and overweight men will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with autonomous nervous system activity</measure>
    <time_frame>10 - 150 minutes post nasal spray</time_frame>
    <description>Correlation of the change in pancreatic insulin secretion by central insulin action with the simultaneous change of the autonomous nervous system (measured by heart rate variability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral insulin sensitivity</measure>
    <time_frame>10-90 min and 70-90 min during hyperglycemic clamp</time_frame>
    <description>Effect of nasal insulin versus placebo on peripheral insulin sensitivity assessed by hyperglycemic hyperinsulinemic clamp.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Insulin Secretion</condition>
  <arm_group>
    <arm_group_label>Insulin nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>160 Units of human insulin as nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal spray containing placebo solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal insulin</intervention_name>
    <arm_group_label>Insulin nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c ≤6.0%

          -  normal glucose tolerance during 75g OGTT

        Exclusion Criteria:

          -  Not removable metal parts in or on the body

          -  manifest cardiovascular disease

          -  claustrophobia

          -  recent surgery (less than 3 months)

          -  Simultaneous participation in other studies

          -  Acute disease or infection within the last 4 weeks

          -  neurological and psychiatric disorders

          -  treatment with centrally acting drugs

          -  hemoglobin Hb &lt;13g / dl

          -  Hypersensitivity to any of the substances used
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Heni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Heni, MD</last_name>
    <phone>+49 7071 29 82714</phone>
    <email>martin.heni@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Fritsche, MD</last_name>
    <phone>+49 7071 29 82714</phone>
    <email>andreas.fritsche@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Tuebingen, Department of Internal Medicine IV</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Heni, MD</last_name>
      <phone>+49 7071 29 82714</phone>
      <email>martin.heni@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Fritsche, MD</last_name>
      <phone>+49 7071 29 82714</phone>
      <email>andreas.fritsche@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>February 9, 2017</lastchanged_date>
  <firstreceived_date>August 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
